Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MPH966

PreclinicalSmall molecule

NNational Cancer Institute (NCI)

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Graft Vs Host DiseaseActive, not recruiting

Chronic Graft Vs Host DiseasePreclinical

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Chronic Graft Vs Host Disease

NCT02669251

Clinical

Trials by Indication[1]

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Withdrawn·NNelson Chao·Phase 1/2·NCT03986086

Chronic Graft vs Host Disease1 trial

A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02669251·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MPH966. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MPH966 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MPH966. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Cancer Institute (NCI)

Related News